| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 10,673 | 12,218 | ||
| General and administrative | 4,475 | 4,843 | ||
| Total operating expenses | 15,148 | 17,061 | ||
| Loss from operations | -15,148 | -17,061 | ||
| Interest income | 1,269 | 1,386 | ||
| Other income/ (expense), net | 0 | 0 | ||
| Total other income, net | 1,269 | 1,386 | ||
| Net loss | -13,879 | -15,675 | ||
| Earnings per share, diluted, total | -0.62 | -0.7 | ||
| Net loss per common share - basic | -0.62 | -0.7 | ||
| Weighted average number of shares outstanding, basic, total | 22,386,000 | 22,356,000 | ||
| Weighted average number of shares outstanding, diluted, total | 22,386,000 | 22,356,000 | ||
Boundless Bio, Inc. (BOLD)
Boundless Bio, Inc. (BOLD)